Clinical Efficacy of Bimekizumab Treatment Up to 2 Years Across Patients With Psoriatic Arthritis and Varying Baseline Joint Involvement: Results From a Post Hoc Analysis of Two Pooled Phase 3 Studies

Bimzelx (bimekizumab-bkzx) - UCB

David Nicholls1; Philip J. Mease2; Laure Gossec3; Hideto Kameda4; Proton Rahman5; Barbara Ink6; Rajan Bajracharya6; Patrick Healy7; Laura C Coates8

May 26, 2026